← Leaderboards
Xiuli An
New York Blood Center
$8,630,004
Attributed
$12,144,421
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2014–25$2.5M$1.9M$1.3M$625K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,144,421 · 7
By mechanism
R01$6,952,596 · 4
P01$4,387,825 · 2
R56$804,000 · 1
Top collaborators
- Cheryl Ann Lobo4 shared
- Connie Marie Westhoff4 shared
- Hui Zhong4 shared
Most similar at New York Blood Center
Same institution · by research overlap
- Cheryl Ann Lobo$8,181,413
- Anna R Migliaccio$7,273,775
- Hui Zhong$1,617,308
- Karina Yazdanbakhsh$18,887,767
- Shan Su$427,000
Others in their field
Top investigators on “Production”
- Eric S Lander · Whitehead Institute For Biomedical Res$568,626,051
- Bambra Strokes · Ppd Development Lp$526,656,217
- Richard A Gibbs · Baylor College Of Medicine$521,766,399
- Tracy L Nolen · Research Triangle Institute$451,761,218
- Sonia M Thomas · Research Triangle Institute$451,761,218
- David Heimbrook · Leidos Biomedical Research, Inc.$332,994,970
Research focus
ProductionErythropoiesisErythroblastsMediatingMolecularIn VivoIn VitroErythroid CellsCellsTransfusionErythroidPlayAntibodiesSignal TransductionErythrocytesMouse ModelAnemiaMacrophageImpairmentHemolysisEpor GeneGenesSickle Cell AnemiaNew Therapeutic Target
Grant awards (18)
Transfusion-driven hyperhemolysis in sickle cell disease$815,643
R01 · FY2025 · HL · contact PI
Erythroblastic island macrophages in normal erythropoiesis and disordered erythropoiesis in polycythemia vera$801,628
R01 · FY2025 · HL · contact PI
Erythroblastic Island Macrophages in SCD Disordered Erythropoiesis.$640,500
P01 · FY2025 · HL · contact PI
Transfusion-driven hyperhemolysis in sickle cell disease$799,330
R01 · FY2024 · HL · contact PI
Hemolysis and the Hematopoietic Niche$737,425
P01 · FY2024 · HL · contact PI
Transfusion-driven hyperhemolysis in sickle cell disease$815,643
R01 · FY2023 · HL · contact PI
Hemolysis and the Hematopoietic Niche$752,475
P01 · FY2023 · HL · contact PI
Transfusion-driven hyperhemolysis in sickle cell disease$804,000
R56 · FY2022 · HL · contact PI
Hemolysis and the Hematopoietic Niche$752,475
P01 · FY2022 · HL · contact PI
Hemolysis and the Hematopoietic Niche$752,475
P01 · FY2021 · HL · contact PI
Use of forward Genetic approaches to identify Babesia receptors$710,081
R01 · FY2021 · HL
Hemolysis and the Hematopoietic Niche$752,475
P01 · FY2020 · HL · contact PI
Use of forward Genetic approaches to identify Babesia receptors$718,981
R01 · FY2020 · HL
Use of forward Genetic approaches to identify Babesia receptors$718,981
R01 · FY2019 · HL
Use of forward Genetic approaches to identify Babesia receptors$697,621
R01 · FY2018 · HL
TET3 in Terminal Erythroid Differentiation$291,769
R01 · FY2016 · DK · contact PI
TET3 in Terminal Erythroid Differentiation$289,537
R01 · FY2015 · DK · contact PI
TET3 in Terminal Erythroid Differentiation$293,382
R01 · FY2014 · DK · contact PI